MitraClip Effective for Post-MI Acute MR With Cardiogenic Shock MitraClip Effective for Post-MI Acute MR With Cardiogenic Shock
Percutaneous mitral valve repair with the MitraClip appears to be a safe, effective, and life-saving treatment for severe acute MR secondary to MI in surgical noncandidates, according to IREMMI data.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 19, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

Women With AMI - Cardiogenic Shock Treated Less Aggressively
Coronary angiography, PCI, mechanical circulatory support used less often; mortality higher (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - September 29, 2020 Category: Respiratory Medicine Tags: Cardiology, Family Medicine, Gynecology, Internal Medicine, Critical Care, Emergency Medicine, Pulmonology, Journal, Source Type: news

Women With AMI-Cardiogenic Shock Treated Less Aggressively
TUESDAY, Sept. 29, 2020 -- Among young adults with acute myocardial infarction-cardiogenic shock (AMI-CS), women are treated less aggressively and have higher in-hospital mortality than men, according to a study published online Sept. 29 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 29, 2020 Category: Pharmaceuticals Source Type: news

HIV Patients Don't Have Worse Outcome After MI With Cardiogenic Shock HIV Patients Don't Have Worse Outcome After MI With Cardiogenic Shock
Outcomes of myocardial infarction-cardiogenic shock (AMI-CS) in patients with HIV but without AIDS are no worse than in patients without HIV, according to new findings.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - August 31, 2020 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Heart attack warning: How often do you pee? It could be a symptom of cardiogenic shock
A HEART ATTACK - otherwise known as a myocardial infarction - occurs when the blood supply to the heart has been blocked. Symptoms of the condition include chest pain, shortness of breath and feeling lightheaded. However, that may not be the worst of it. (Source: Daily Express - Health)
Source: Daily Express - Health - August 16, 2020 Category: Consumer Health News Source Type: news

DoD Funds Clinical Trial of Seraph Blood Filter to Treat COVID-19
The Department of Defense is funding a clinical trial of a COVID-19 treatment using ExThera Medical’s Seraph 100 Blood filter. The device was selected to be in the multi-center randomized clinical trial because it showed encouraging preliminary results in critically ill COVID-19 patients at a military hospital in the U.S. and 14 other hospitals in Europe. Investigators at the Uniformed Services University in Bethesda will run the trial of the Martinez, CA-based company’s device. Initial reports indicate Seraph 100 stabilizes blood pressure and inflammatory biomarkers that correlate with ...
Source: MDDI - June 10, 2020 Category: Medical Devices Authors: Omar Ford Tags: COVID-19 Business Source Type: news

Abiomed Granted IDE to Evaluate ‘World’s Smallest Heart Pump’
Abiomed said it has received approval for an IDE to start an early feasibility study of what it is calling the “world’s smallest heart pump.”   The Danvers, MA-based company said the first-in-human trial will look at the 9 French Impella ECP heart pump in high-risk percutaneous coronary intervention (PCI) patients.   The primary endpoint of the study is successful delivery, initiation, and maintenance of adequate hemodynamic support and a composite rate of major device-related adverse events during high-risk PCI.   The stu...
Source: MDDI - June 6, 2020 Category: Medical Devices Tags: Cardiovascular Regulatory and Compliance Source Type: news

Mounting Use of'Primary' TAVR in Shock from Aortic Stenosis Mounting Use of'Primary' TAVR in Shock from Aortic Stenosis
' Can we claim the use of TAVR as the first-line therapy in any patient admitted with cardiogenic shock and aortic stenosis,'observers asked. The observational study's results are'encouraging. 'Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 4, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

New Acquisition Could Give Abiomed Access to Help COVID-19 Patients
Abiomed, maker of the Impella heart pump, could have the chance to reach some COVID-19 patients with its latest acquisition. The Danvers, MA-based company said it acquired Breethe, a developer of an extracorporeal membrane oxygenation system for an undisclosed sum. Breethe has applied for a 510K clearance of the ECMO system. The Baltimore, MD-based company’s technology has the potential to serve the needs of patients whose lungs can longer provide sufficient oxygenation, including patients suffering from cardiogenic shock, cardiac arrest or respiratory failure such as due to ARDS, H1N1, SARS, or COVID-19....
Source: MDDI - May 1, 2020 Category: Medical Devices Authors: Omar Ford Tags: COVID-19 Cardiovascular Source Type: news

CABG Tied to Lower Death Rate in MI Complicated by Cardiogenic Shock CABG Tied to Lower Death Rate in MI Complicated by Cardiogenic Shock
Coronary-artery-bypass grafting (CABG) is associated with lower in-hospital mortality in myocardial infarction (MI) complicated by cardiogenic shock, compared with percutaneous coronary intervention (PCI), according to a database study.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - April 7, 2020 Category: Surgery Tags: Cardiology News Source Type: news

Controversies in Cardiogenic Shock Controversies in Cardiogenic Shock
Dr Ileana Pi ñ a discusses controversies surrounding cardiogenic shock, including data presented at the AHA Scientific Sessions 2019.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 23, 2020 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news

The War on Shock: Is Industry Leading the Charge? The War on Shock: Is Industry Leading the Charge?
Protocols for patients in cardiogenic shock encourage use of mechanical circulatory support and play down palliative care, despite limited supporting data, writes interventional cardiologist Jaya Mallidi.theheart.org on Medscape (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - January 6, 2020 Category: Surgery Tags: Cardiology Commentary Source Type: news

New Cardiogenic Shock Staging System IDs Mortality Risk
MONDAY, Dec. 9, 2019 -- The new Society for Cardiovascular Angiography and Intervention (SCAI) cardiogenic shock (CS) classification scheme provides risk stratification for hospital mortality, according to a study recently published in the Journal... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 9, 2019 Category: Pharmaceuticals Source Type: news

Impella Bleeding, Mortality'Signals' in MI-Shock, High-Risk PCI Impella Bleeding, Mortality'Signals' in MI-Shock, High-Risk PCI
Is it reality-check time for aficionados of Impella ventricular-assist pumps in cardiogenic shock or supported PCI? New observational data raise cautions given the thin randomized trial support.Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - November 26, 2019 Category: Intensive Care Tags: Cardiology News Source Type: news

Mandrola Previews 2019 AHA and the ISCHEMIA Trial Mandrola Previews 2019 AHA and the ISCHEMIA Trial
All eyes will be on ISCHEMIA in Philadelphia, but a study on asymptomatic aortic stenosis as well as trials in heart failure and cardiogenic shock also piqued Dr John Mandrola's interest.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 12, 2019 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news

Penumbra Looks to Bolster Indigo Through CHEETAH
The first patient has been enrolled in Penumbra’s CHEETAH post-market study to evaluate the Indigo System with CAT RX Aspiration Catheter in the coronary vessels. About 400 patients are expected to be enrolled at 25 centers in CHEETAH. Alameda, CA-based Penumbra’s Indigo System uses mechanical power aspiration to remove thrombus in the coronaries. The primary study endpoint is a composition of cardiovascular (CV) death, recurrent myocardial infarction (MI), cardiogenic shock or new or worsening New York Heart Association (NYHA) Class IV heart failure within 30 days. Secondary endpoints i...
Source: MDDI - October 11, 2019 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Business Source Type: news

Management of Cardiogenic Shock Complicating MI Management of Cardiogenic Shock Complicating MI
Cardiogenic shock remains the most common cause of death in patients with acute myocardial infarction. What are the current best options for the management of cardiogenic shock complicating AMI?European Heart Journal (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - September 25, 2019 Category: Intensive Care Tags: Cardiology Journal Article Source Type: news

Shock and Awe: ARNI for Acute HF May Be Safely Started in ICU Shock and Awe: ARNI for Acute HF May Be Safely Started in ICU
Some patients in cardiogenic shock may transition from IV vasoactive agents to sacubitril/valsartan without going hypotensive, suggests a small case series; PA-pressure guidance was crucial.Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - September 17, 2019 Category: Intensive Care Tags: Cardiology News Source Type: news

New SCAI Statement on Classification of Cardiogenic Shock New SCAI Statement on Classification of Cardiogenic Shock
Patients presenting with cardiogenic shock run the gamut from mildly ill to near death. This statement presents a first-ever classification to create a common lexicon for rapid triage.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 13, 2019 Category: Consumer Health News Tags: Cardiology News Source Type: news

Classification System Developed for Cardiogenic Shock
THURSDAY, May 23, 2019 -- A classification system has been developed for categorizing cardiogenic shock; the consensus statement, endorsed by the American College of Cardiology, American Heart Association, Society of Critical Care Medicine, and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 23, 2019 Category: Pharmaceuticals Source Type: news

FDA Says Patient Selection is Key to Abiomed Impella RP Safety
The benefits Abiomed's Impella RP System outweigh the risks of the device, but only if it is used for the currently approved indication in appropriately selected patients, according to FDA's latest letter about the device. FDA said the latest interim results indicate a lower survival rate for the subgroup of post-approval study patients who would not have qualified for the premarket clinical studies compared to the premarket clinical study survival rate. The agency reported that the most recent post-approval study report shows 12 out of the 42 patients (28.6%) survived to 30 days post device explant or hospital...
Source: MDDI - May 21, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Regulatory and Compliance Cardiovascular Source Type: news

New Approval Extends Impella ’s Support Time
Abiomed has received a nod from FDA to expand the Impella 5.0 and Impella LD PMA’s labeling for the treatment of cardiogenic shock. The agency has approved the Danvers, MA-based company’s Impella to provide support 10 to 14 days. Prior to the expansion, the pump was only at six days. Abiomed’s Impella 5.0 and the Impella LD are forward flow heart pumps that deliver up to 5 L/min, stabilizing a patient’s hemodynamics, unloading the left ventricle, and perfusing the end organs, allowing for the potential of native heart recovery or return to heart functi...
Source: MDDI - May 14, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

Cardiac Assist Devices in Cardiogenic Shock Cardiac Assist Devices in Cardiogenic Shock
A new study examines the use of the Impella CP cardiac assist device in patients with acute MI complicated by cardiogenic shock. What are the implications of the findings?Circulation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 19, 2019 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Abiomed touts new Impella study results
Abiomed’s Impella 2.5 pump (Image from Abiomed) New data on Abiomed (NSDQ:ABMD) Impella heart pumps show a 34% increase in survival among nearly 5,000 patients treated with the company’s devices intended to treat cardiogenic shock when combined with best practices, according to a company study. The study of patients treated at 763 U.S. sites between April 1, 2018 and March 28, 2019 showed median survival rates had risen from 51% in 2016, when the FDA granted premarket approval for the Impella 2.5, CP, 5.0 and LD heart pumps, to 67%, the Danvers, Mass.-based company said. (The FDA approved Impella 2.5 ...
Source: Mass Device - April 5, 2019 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Source Type: news

ACC 2019 Roundup: Abiomed Impella RP post-market study shows benefit in select patient group
Abiomed (NSDQ:ABMD) today released 18-month post-approval study data from patients treated with its Impella RP, touting a benefit to survival for specifically selected “Recover Right” protocol patients. Results from the study were presented at the American College of Cardiology’s 68th Annual Scientific Sessions in New Orleans, the Danvers, Mass.-based company said. The review follows a release posted by the FDA last month warning of a 17.4% survival rate with the Impella RP heart pump system, approximately 55% lower than the rate noted in the premarket study of the device. Abiomed said that it met wi...
Source: Mass Device - March 18, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Assist Devices Cardiac Implants Cardiovascular Featured Patient Monitoring Replacement Heart Valves Abbott Abiomed Medtronic Source Type: news

A Push for Push Dose Epinephrine
You transport a 79-year-old woman to the hospital for fever and urinary incontinence. Her family mentions a history of frequent urinary tract infections. Her initial vital signs are a heart rate of 115 bpm, an oxygen saturation of 97% on room air, and a blood pressure of 105/75 mmHg. You establish a peripheral IV line and begin a bolus of normal saline. About 15 minutes away from the hospital, you note the patient becomes increasingly drowsy. Her heart rate has increased to 125 bpm and her blood pressure is now 85/47 mmHg. What are your next steps? Prehospital Shock Starting in 2018, push dose epinephrine replaced dopamine...
Source: JEMS Patient Care - March 14, 2019 Category: Emergency Medicine Authors: Sammy Hodroge, MD Tags: Training Cardiac & Resuscitation Top Story Exclusive Articles Patient Care Source Type: news

A Nail in the Coffin for IABP in AMI With Cardiogenic Shock A Nail in the Coffin for IABP in AMI With Cardiogenic Shock
A 6-year follow-up of the IABP-SHOCK II study confirms lack of benefit on mortality associated with IABP placement in the setting of MI-associated cardiogenic shock.Circulation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 19, 2019 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Life and Times of Leading Cardiologists: Holger Thiele Life and Times of Leading Cardiologists: Holger Thiele
Holger Thiele's career in cardiogenic shock began in West Berlin where he witnessed the fall of the wall and moved to Leipzig to pursue cardiology. This former ironman still bikes to the hospital.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 14, 2019 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news

FDA: Interim data from post-market Abiomed Impella RP study shows 17% survival rate
The FDA yesterday said that interim data from a post-approval study of Abiomed‘s (NSDQ:ABMD) Impella RP heart pump system showed only a 17.4% survival rate, approximately 55% lower than the rate noted in the premarket study of the device. The federal watchdog said that it is currently evaluating data from the study and that it will continue to monitor survival rates, but added that it still believes the system’s benefits outweigh the risks when used correctly. In premarket clinical trials, results indicated a 73.3% survival rate to 30 days post device explant or hospital discharge, or to the start of the n...
Source: Mass Device - February 5, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Assist Devices Cardiovascular Clinical Trials Featured Food & Drug Administration (FDA) Abiomed Source Type: news

AHA: Cardiogenic Shock Ups Mortality in Takotsubo Syndrome
TUESDAY, Nov. 13, 2018 -- For patients with takotsubo syndrome (TTS), those with cardiogenic shock (CS) have an increased risk for mortality, according to a research letter published online Nov. 10 in Circulation to coincide with the annual meeting... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 13, 2018 Category: Pharmaceuticals Source Type: news

Abiomed shares slide despite Impella CP trial success
Abiomed (NSDQ:ABMD) shares fell approximately 13.1% yesterday despite the company announcing positive results from a pilot trial of its Impella CP heart pump that will clear the way for a pivotal that could nearly double the device’s total addressable market. The company announced on Sunday that a pilot study of its Impella CP, used to unload the left ventricle for patients presenting with anterior ST-segment elevation myocardial infarction without cardiogenic shock met its primary endpoints and that it plans to launch a pivotal trial during the second half of next year. Leerink Partner analyst Danielle Antalffy...
Source: Mass Device - November 13, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Cardiac Assist Devices Cardiovascular Catheters Featured Wall Street Beat Abiomed Source Type: news

Abiomed ’s Successful Pilot Study Leads to Pivotal Trial
Abiomed shares were down as much as 17% despite announcing positive data for its Impella CP. The Danvers, MA-based company presented the data from the 50-patient pilot trial at the American Heart Association annual conference in Chicago and said because of the favorable data it would now move to a pivotal trial. The results of the FDA STEMI Door-to-Unloading safety and feasibility randomized controlled trial, show unloading the left ventricle with Impella CP for 30 minutes prior to reperfusion in patients presenting with anterior ST-segment elevation myocardial infarction (STEMI) without cardiogenic shock is safe and feasi...
Source: MDDI - November 12, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

Medical News Today: Broken heart syndrome: How complications affect death risk
New research has examined the effect of cardiogenic shock on long- and short-term mortality risk among people with broken heart syndrome. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 8, 2018 Category: Consumer Health News Tags: Heart Disease Source Type: news

Abiomed Responds to MedSun Report on Two Impella Pumps
Editor's note: This story has been updated from the original story to include comments from Abiomed. A report published through FDA's medical product safety network (MedSun) database describes two issues that involve Abiomed's Impella heart pumps. However, the company told MD+DI that the information in the MedSun report is inaccurate. According to the report, which is located here on FDA's website, one Impella pump reportedly had an unknown "material" inside the pump, causing it to have flows "less than expected," and another pump's housing/outlet cage and impeller we...
Source: MDDI - October 12, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Implants Source Type: news

Benefit Persists for Culprit-Lesion-Only PCI in MI With Shock Benefit Persists for Culprit-Lesion-Only PCI in MI With Shock
One-year follow-up of the CULPRIT-SHOCK trial shows the advantage conferred by PCI only of the culprit lesion vs immediate multivessel PCI at 30 days persists in MI complicated by cardiogenic shock.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 26, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

ESC: Multivessel PCI Disappoints Longer-Term in Cardiogenic Shock
(MedPage Today) --'Less is more'still true in CULPRIT-SHOCK trial (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 25, 2018 Category: Cardiology Source Type: news

Abiomed shares down despite Street-beating FY2019 Q1, Indian Impella approval
Shares in Abiomed (NSDQ:ABMD) have fallen today despite the medical device maker posting earnings that beat expectations by Wall Street for its fiscal year 2019 first quarter and announcing approval of its Impella heart pump in India. The Danvers, Mass.-based company posted profits of $90.1 million, or $1.95 per share, on sales of $180 million for the three months ended June 30, seeing profits grow 141% while sales grew 35.9% compared with the same period during the previous year. Earnings per share were well ahead of the 82¢ consensus on Wall Street, where analysts expected to see sales of $173.2 million, w...
Source: Mass Device - July 26, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Cardiac Assist Devices Cardiovascular MassDevice Earnings Roundup Regulatory/Compliance Wall Street Beat Abiomed Source Type: news

Study: Epinephrine May Not Be Best Choice for Cardiogenic Shock in MI
(MedPage Today) -- Associated with higher rates of refractory shock than with norepinephrine (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - July 3, 2018 Category: Cardiology Source Type: news

Study: Epinephrine Not Best Choice for Cardiogenic Shock in MI
(MedPage Today) -- Higher rates of refractory shock than with norepinephrine (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - July 3, 2018 Category: Cardiology Source Type: news

Abiomed Earns FDA Approval for Adding Optical Sensor to Impella CP Heart Pump
Abiomed, which had a busy 2017 and was among our Company of the Year finalists, reported today that it has received FDA premarket approval (PMA) for its Impella CP heart pump with SmartAssist, utilizing an optical sensor. The sensor is one component of the SmartAssist technology, which also includes a software update enabling informational displays of left ventricular pressure (LVP), end-diastolic pressure (EDP), and cardiac power output (CPO) data on the Impella Console, an Abiomed spokesperson told MD+DI. The Impella CP heart pump had already earned FDA approval for treating patients in cardiogenic shock as well as patie...
Source: MDDI - April 2, 2018 Category: Medical Devices Authors: Daphne Allen Tags: Cardiovascular Source Type: news

Abiomed wins expanded Impella FDA nod for elective, urgent high-risk PCI
Abiomed (NSDQ:ABMD) said today it won expanded FDA premarket approval for its Impella 2.5 and Impella CP heart pumps, now cleared for use during elective and urgent high risk percutaneous coronary intervention procedures. With the expansion, the Impella heart pump is cleared for use with patients with severe coronary artery disease, complex anatomy and a number of co-morbidities with or without depressed ejection fractions, the Danvers, Mass.-based company said. “This expanded FDA approval with moderately reduced ejection fraction validates our real-world experience using hemodynamic support in patients turned d...
Source: Mass Device - February 14, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Assist Devices Cardiovascular Catheters Food & Drug Administration (FDA) Regulatory/Compliance Abiomed Source Type: news

Abiomed Receives Approval for Expanded FDA Indication for Cardiomyopathy with Cardiogenic Shock
DANVERS, Mass., Feb. 13, 2018 -- (Healthcare Sales & Marketing Network) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announced today that it has received an expanded U.S. Food and Drug Administ... Devices, Cardiology, FDA Abiomed, Impella, ventricular support, Cardiomyopathy, Cardiogenic Shock (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 13, 2018 Category: Pharmaceuticals Source Type: news

Abiomed touts expanded Impella heart pump indication, launches Women ’s Initiative
Abiomed (NSDQ:ABMD) said today it won expanded FDA premarket approval for its Impella 2.5, Impella CP, Impella 5.0 and Impella LD heart pumps, now cleared to provide treatment for heart failure associated with cardiomyopathy leading to cardiogenic shock, including peripartum and postpartum cardiomyopathy. The approval follows a previous FDA indication the Danvers, Mass.-based company won in April 2016 that cleared the device for treating acute myocardial infarction cardiogenic shock and post-cardiotomy cardiogenic shock. Abiomed touts its Impella heart pumps as the only percutaneous temporary ventricular support ...
Source: Mass Device - February 13, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Assist Devices Cardiovascular Catheters Food & Drug Administration (FDA) Regulatory/Compliance Abiomed Source Type: news

Living too far from advanced cardiac care decreases your odds of survival
(Elsevier) A new study published in the Canadian Journal of Cardiology determined that patients with acute cardiac syndrome (ACS) and cardiogenic shock (CS), who live far from the only cardiac catheterization facility in Nova Scotia, Canada, have a survival rate about half that of patients with more direct access. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 31, 2018 Category: International Medicine & Public Health Source Type: news

Qool Therapeutics raises $8m to support temp management device
Early stage med device developer Qool Therapeutics said today it raised $8 million in a Series A-1 round to support development and trials of its Qool device designed for targeted temperature management and exercise recovery. Joining the funding round was Zhongji Holdings and Join Medical Technology, Tampcap LLC, BrilliMedical International, BioPacific Investors, Western Technology Investment and FundRx, the Silicon Valley-based company said. Qool Therapeutics said that in addition to the funding, it has also received an award from the US Department of Defense’s Defense Innovation unit Experimental organization. The ...
Source: Mass Device - November 28, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Research & Development Respiratory qooltherapeutics Source Type: news

Revascularization in CS: Keep It Simple and Get Out of Dodge Revascularization in CS: Keep It Simple and Get Out of Dodge
Drs Harrington, Batchelor, and O'Donoghue discuss the implications of the TCT late-breaking CULPRIT SHOCK trial testing culprit-only vs multivessel revascularization in unstable patients in cardiogenic shock.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 13, 2017 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news

Nov 3 Cardiology News Nov 3 Cardiology News
The ORBITA sham-control PCI study, Watchman, revascularization in cardiogenic shock, Absorb BVS, quality-of-life outcomes after PCI or bypass, and chronic total occlusion PCI are discussed in this week's podcast.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 3, 2017 Category: Cardiology Tags: Cardiology News Source Type: news

Should patients with cardiogenic shock receive culprit lesion only PCI or multivessel PCI?
(Cardiovascular Research Foundation) Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found that an initial strategy of culprit lesion only percutaneous coronary intervention (PCI) reduces the composite of 30-day mortality and/or severe renal failure in patients with multivessel disease and cardiogenic shock complicating acute myocardial infarction. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 31, 2017 Category: International Medicine & Public Health Source Type: news

Successful cardiogenic shock treatment using a percutaneous left ventricular assist device
(Osaka University) The Cardiovascular Surgery Group at Osaka University succeeded in minimally invasive treatment of a patient with acute heart failure due to medical treatment-resistant cardiogenic shock by making use of Impella, a percutaneous auxiliary artificial heart, for the first time in Japan. This method is anticipated as a new therapy for treating patients with acute heart failure due to medical treatment-resistant cardiogenic shock. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 31, 2017 Category: International Medicine & Public Health Source Type: news

Multivessel PCI Not Best in Cardiogenic Shock
(MedPage Today) -- Trial data show mortality disadvantage versus treating culprit lesions only (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - October 30, 2017 Category: Urology & Nephrology Source Type: news